The number of circulating monocytes as biomarkers of the clinical response to methotrexate in untreated patients with rheumatoid arthritis

被引：55

作者：

Chara, Luis ^{[1
]}

Sanchez-Atrio, Ana ^{[2
]}

Perez, Ana ^{[2
]}

Cuende, Eduardo ^{[2
]}

Albarran, Fernando ^{[2
]}

Turrion, Ana ^{[2
]}

Chevarria, Julio ^{[2
]}

del Barco, Angel Asunsolo ^{[3
]}

Sanchez, Miguel A. ^{[1
]}

Monserrat, Jorge ^{[1
]}

Prieto, Alfredo ^{[1
]}

de la Hera, Antonio ^{[1
]}

Sanz, Ignacio ^{[4
]}

Diaz, David ^{[1
]}

Alvarez-Mon, Melchor ^{[1
,2
]}

机构：

[1] Univ Alcala, Dept Med, Madrid 28871, Spain

[2] Univ Hosp Principe de Asturias, Immune Syst Dis Rheumatol & Oncol Serv, Madrid, Spain

[3] Univ Alcala, Dept Hlth & Med Social Sci, Madrid 28871, Spain

[4] Emory Univ, Dept Med, Div Allergy Immunol & Rheumatol, Atlanta, GA 30322 USA

来源：

JOURNAL OF TRANSLATIONAL MEDICINE | 2015年 / 13卷

关键词：

Rheumatoid arthritis; Monocyte; Methotrexate; Clinical response; Biomarker; BIOCHIP ARRAY TECHNOLOGY; PERIPHERAL-BLOOD; SUBSET; CELLS; RESPONSIVENESS; HETEROGENEITY; MACROPHAGES; VALIDATION; PREDICTORS; BIOLOGICS;

D O I：

10.1186/s12967-014-0375-y

中图分类号：

R-3 [医学研究方法]; R3 [基础医学];

学科分类号：

100103 [病原生物学]; 100218 [急诊医学];

摘要：

Background: The aim of this work was to analyze the number and distribution of circulating monocytes, and of their CD14(+high)CD16(-), CD14(+high)CD16(+) and CD14(+low)CD16(+) subset cells, in treatment-naive patients with rheumatoid arthritis (RA), and to determine their value in predicting the clinical response to methotrexate (MTX) treatment. Methods: This prospective work investigated the number of circulating monocytes, and the numbers of CD14 (+high)CD16(-), CD14(+high)CD16(+) and CD14(+low)CD16(+) subset cells, in 52 untreated patients with RA before MTX treatment, and at 3 and 6 months into treatment, using flow cytometry. Results: The absolute number of circulating monocytes, and the numbers of CD14(+high)CD16(-), CD14(+high)CD16(+) and CD14(+low)CD16(+) subset cells, were significantly higher in MTX non-responders than in responders and healthy controls before starting and throughout treatment. Responders showed normal numbers of monocytes, and of their subset cells, over the study period. The pre-treatment absolute number of circulating monocytes, and the numbers of CD14(+high)CD16(-) and CD14(+high)CD16(+) subset cells, were found to be predictive of the clinical response to MTX, with a sensitivity and specificity of >70% and >88%, respectively. Conclusions: Treatment-naive patients with RA showed an anomalous distribution of circulating monocyte subsets, and an anomalous number of cells in each subset. A higher pre-treatment number of circulating monocytes, and higher numbers of CD14(+high)CD16(-) and CD14(+high)CD16(+) subset cells, predict a reduced clinical response to MTX in untreated patients with RA.

引用

页数：10

共 37 条

[1]

Blood Monocytes: Development, Heterogeneity, and Relationship with Dendritic Cells [J].